Merck KGaA to appeal against negative CHMP opinion on Cladribine
This article was originally published in Scrip
Executive Summary
Merck KGaA has told the EMA that it wants a re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) negative opinion on Cladribine Tablets for treating relapsing-remitting multiple sclerosis (RRMS).